Nonmelanoma Skin Cancer Market
- Basal cell carcinoma accounts for around 80% of skin cancer cases. It usually develops in places that have been exposed to the sun, such as the face and neck. Squamous cell carcinoma makes up roughly the other 20% of all cases of skin cancer.
- The leading Nonmelanoma Skin Cancer Companies such as Sensus Healthcare, DUSA Pharmaceuticals Inc, Skin Analytics Limited, Pfizer, Bristol-Myers Squibb, and others.
- Nonmelanoma Skin Cancer epidemiology is segmented as Total prevalent cases of Nonmelanoma Skin Cancer, Total diagnosed prevalent cases of Nonmelanoma Skin Cancer, Gender-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, Age-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, and Region-specific diagnosed prevalent cases in the Nonmelanoma Skin Cancer Market Report.
Request for Unlocking the Sample Page of the "Nonmelanoma Skin Cancer Treatment Market"
DelveInsight's "Nonmelanoma Skin Cancer Market Insights, Epidemiology, and Market Forecast — 2034" report delivers an in-depth understanding of the Nonmelanoma Skin Cancer, historical and forecasted epidemiology as well as the Nonmelanoma Skin Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan.
The Nonmelanoma Skin Cancer Treatment Market Report provides current treatment practices, emerging drugs, Nonmelanoma Skin Cancer market share of the individual therapies, current and forecasted Nonmelanoma Skin Cancer market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Nonmelanoma Skin Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
| Study Period | 2020 to 2034 |
| Forecast Period | 2024-2034 |
| Geographies Covered |
|
| Nonmelanoma Skin Cancer Market |
|
| Nonmelanoma Skin Cancer Market Size | |
| Nonmelanoma Skin Cancer Companies |
|
Non-melanoma Skin Cancer Treatment Market
The DelveInsight’s Nonmelanoma Skin Cancer market report gives a thorough understanding of Nonmelanoma Skin Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. The skin is made of a variety of cells, many of which are in constant motion. Round basal cells below the surface flatten as they rise to replace dead, flaking squamous cells on the surface. Melanocytes tan the skin in the sunlight, and Merkel cells give skin its ability to sense touch. When these cells become damaged, they may develop into skin cancer.
Skin cancer can be further classified into melanoma and nonmelanoma. Skin cancers that are not melanomas are sometimes grouped as nonmelanoma skin cancers (NMSCs) because they develop from skin cells other than melanocytes. They tend to behave very differently from melanomas and are often treated with different methods. Several types of skin cancer fall within the broader category of nonmelanoma skin cancer, but the primary forms are basal cell carcinoma, squamous cell carcinoma.
Other types of Nonmelanoma Skin Cancer are much less common than basal and squamous cell cancers and are treated differently. They include Merkel cell carcinoma, Kaposi sarcoma, Cutaneous (skin) lymphoma, and others.
Non-melanoma Skin Cancer Diagnosis
Because non-melanoma skin cancer rarely spreads, a biopsy is often the only test needed to diagnose and find out the stage, or extent, of cancer. Further Nonmelanoma Skin Cancer clinical trial examination is required to rule out the disease. A health history, skin exam and skin biopsy are commonly used to rule out or diagnose non-melanoma skin cancer.
Nonmelanoma Skin Cancer Treatment
Nonmelanoma Skin Cancer treatment is determined on a case-by-case basis, depending on many factors, such as the type and stage of cancer, the size and location of the tumor and the patient’s medical history and overall health. Nonsurgical treatments, such as freezing (cryotherapy), anti-cancer creams, photodynamic therapy (PDT), radiotherapy and electrochemotherapy, are also used in certain circumstances.
Drug therapy is sometimes used to treat Nonmelanoma skin cancer. Topical therapy uses a cream or gel to put drugs directly on the skin. The topical therapy drugs used for non-melanoma skin cancer are imiquimod (Aldara, Zyclara) and 5-fluorouracil (5-FU, Efudex, Actikerall). Imiquimod is a type of immunotherapy drug called an immune response modifier. It uses your immune system to help destroy cancer cells. It may be used to treat small, superficial basal cell carcinoma (BCC) on the neck, trunk, arms or legs. 5-fluorouracil is a chemotherapy drug used to treat a specific area on the skin. Topical 5-fluorouracil is used primarily for precancerous conditions of the skin, such as actinic keratosis.
Nonmelanoma Skin Cancer Epidemiology
The Nonmelanoma Skin Cancer epidemiology section provides insights about historical and current Nonmelanoma Skin Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
- Basal cell carcinoma accounts for around 80% of skin cancer cases. It usually develops in places that have been exposed to the sun, such as the face and neck. Squamous cell carcinoma makes up roughly the other 20% of all cases of skin cancer.
- The disease epidemiology covered in the report provides historical as well as forecasted Nonmelanoma Skin Cancer epidemiology [segmented as Total prevalent cases of Nonmelanoma Skin Cancer, Total diagnosed prevalent cases of Nonmelanoma Skin Cancer, Gender-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, Age-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, Region-specific diagnosed prevalent cases of Nonmelanoma Skin Cancer, and Treatable cases of Nonmelanoma Skin Cancer] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
Country Wise- Nonmelanoma Skin Cancer Epidemiology
This section provides glimpse of the Nonmelanoma Skin Cancer epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Nonmelanoma Skin Cancer Prevalence
Nonmelanoma Skin Cancer Recent Developments
- In December 2024, AiViva Biopharma Inc., a clinical-stage biotechnology company, announced FDA clearance to test AIV001 (axitinib) via intradermal injection in facial skin. AIV001 is a pan-tyrosine kinase inhibitor in a proprietary formulation designed for prolonged drug release. The clearance was based on safety data from 67 subjects treated with AIV001 for BCC and scar management, showing non-facial skin tolerability and systemic exposure.
Nonmelanoma Skin Cancer Drug Chapters
The drug chapter segment of the Nonmelanoma Skin Cancer therapeutics market report encloses the detailed analysis of Nonmelanoma Skin Cancer marketed drugs and late stage (Phase-III and Phase-II) Nonmelanoma Skin Cancer pipeline drugs analysis. It also helps to understand the Nonmelanoma Skin Cancer clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Non-melanoma Skin Cancer Marketed Drugs
- VISMODEGIB (erivedge): Genentech
Initially approved in 2012, vismodegib is the first FDA-approved pharmacologic agent that targets the Hedgehog signaling pathway (sonic hedgehog, SHH), a pathway involved in many basal cell carcinomas. In January 2012, the FDA approved vismodegib (Erivedge, Genentech), the first oral medication for adults with meta-static BCC or locally advanced BCC that has recurred after surgery or for patients who are not candidates for surgery or radiation.
- LIBTAYO (cemiplimab-rwlc): Sanofi
Recently in September 2021, The US Food and Drug Administration (FDA) has approved the PD-1 inhibitor LIBTAYO (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.
Nonmelanoma Skin Cancer Emerging Drugs
Sirnaomics product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of the company’s proprietary dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-β1 and COX-2 gene expression directly. Sirnaomics has opened Investigational New Drug (IND) applications under the jurisdiction of the US FDA and Chinese FDA for clinical studies for NMSCs, cholangiocarcinoma, and hypertrophic scar reduction. The drug is currently in Phase II for basal cell carcinoma and cutaneous squamous cell carcinoma (in situ).
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. The drug is currently in Phase I/II for Nonmelanoma Skin Cancer.
Nonmelanoma Skin Cancer Market Outlook
Nonmelanoma Skin Cancer treatment is determined on a case-by-case basis, depending on many factors, such as the type and stage of cancer, the size and location of the tumor and the patient’s medical history and overall health. Nonsurgical treatments, such as freezing (cryotherapy), anti-cancer creams, photodynamic therapy (PDT), radiotherapy and electrochemotherapy, are also used in certain circumstances.
The Nonmelanoma Skin Cancer coverage and support is one of the major drivers fueling growth in the non-melanoma skin cancer market. Direct medical expenses for treating Nonmelanoma skin cancer include pathology fees, facility fees, diagnosis fees, treatment fees, repair fees, and other incidentals. Medicare and the majority of payers reimburse the costs of surgeries as part of treatment. Compared to surgery, the majority of pharmacological techniques demand significant effort and several doctor visits. Most of the medications for Nonmelanoma Skin Cancer are paid for by the manufacturing business in the form of patient support and discount vouchers for low-income populations.
Vismodegib is used for metastatic BCC or locally advanced BCC when surgery or radiation therapy cannot be used. Vismodegib is given daily as a pill by mouth (orally). It is usually given as long as the drug is working or unless the side effects outweigh the treatment benefits.
Systemic chemotherapy is usually only used for locally advanced or non-melanoma skin cancer that has spread (metastasized). Some common chemotherapy drugs used are cisplatin (Platinol AQ) and paclitaxel (Taxol). These are given with a needle into a vein (intravenously). For some advanced or metastatic SCC cases, other drugs may be combined with chemotherapy, such as interferon alfa (Intron A, Wellferon) or retinoid drugs. There is no standard chemotherapy treatment plan for non-melanoma skin cancer.
In February 2021, the US FDA approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC, and accelerated approval was granted for patients with metastatic BCC.
Pembrolizumab also received approval from the US FDA for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. The Nonmelanoma Skin Cancer Market Dynamics is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key Nonmelanoma Skin Cancer Companies such as Sirnaomics, AiViva BioPharma, Exicure and many more, are developing NMSC drugs.
According to DelveInsight, Non-melanoma Skin Cancer Treatment Market in 7MM is expected to witness a major change in the study period 2020-2034.
Get More Insights @ PD-1 inhibitor Market
Analyst Commentary
- The Nonmelanoma Skin Cancer Pipeline is very robust, many potential therapies are being investigated for the treatment of Nonmelanoma Skin Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
- The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Non-melanoma Skin Cancer market in the 7MM. Aside from that, the market size of Nonmelanoma Skin Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
- The market growth of Nonmelanoma Skin Cancer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Nonmelanoma Skin Cancer Drugs Uptake
This section focusses on the rate of uptake of the potential Nonmelanoma Skin Cancer drugs recently launched in the Non-melanoma Skin Cancer Drugs Market or expected to get launched in the market during the study period 2020-2034. The analysis covers Non-melanoma Skin Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new Nonmelanoma Skin Cancer drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Nonmelanoma Skin Cancer Pipeline Development Activities
The Nonmelanoma Skin Cancer Therapeutics Market Report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Nonmelanoma Skin Cancer Companies involved in developing targeted therapeutics.
Pipeline Development Activities
The Nonmelanoma Skin Cancer Therapeutics Market Report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Nonmelanoma Skin Cancer emerging therapies.
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Nonmelanoma Skin Cancer Treatment Drugs
Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Nonmelanoma Skin Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Non-melanoma Skin Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Non-melanoma Skin Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Nonmelanoma Skin Cancer Treatment Market Report Scope
- The Nonmelanoma Skin Cancer treatment market report covers the descriptive overview, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Nonmelanoma Skin Cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Nonmelanoma Skin Cancer are provided, along with the assessment of new therapies, which will have an impact on the current Nonmelanoma Skin Cancer treatment market landscape
- A detailed review of the Nonmelanoma Skin Cancer treatment market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Nonmelanoma Skin Cancer drugs market
Non-melanoma Skin Cancer Treatment Market Report Highlights
- In the coming years, the Nonmelanoma Skin Cancer therapeutics market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The Nonmelanoma Skin Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Nonmelanoma Skin Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major Nonmelanoma Skin Cancer Companies are involved in developing therapies for Nonmelanoma Skin Cancer. The launch of emerging therapies will significantly impact the Nonmelanoma Skin Cancer market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Nonmelanoma Skin Cancer
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Nonmelanoma Skin Cancer Clinical Trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Non-melanoma Skin Cancer Treatment Market Report Insights
- Patient Based Market Forecasting
- Nonmelanoma Skin Cancer Therapeutic Approaches
- Nonmelanoma Skin Cancer Pipeline Drugs Analysis
- Non-melanoma Skin Cancer Market Size and Trends
- Nonmelanoma Skin Cancer Drugs Market Opportunities
- Impact of upcoming Therapies
Non-melanoma Skin Cancer Treatment Market Report Key Strengths
- 11 Years Nonmelanoma Skin Cancer Market Forecast
- 7MM Coverage
- Nonmelanoma Skin Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Nonmelanoma Skin Cancer Drugs Market
- Nonmelanoma Skin Cancer Drugs Uptake
Non-melanoma Skin Cancer Treatment Market Report Assessment
- Current Nonmelanoma Skin Cancer Treatment Market Practices
- Nonmelanoma Skin Cancer Unmet Needs
- Nonmelanoma Skin Cancer Pipeline Drugs Profiles
- Nonmelanoma Skin Cancer Drugs Market Attractiveness
Key Questions
Nonmelanoma Skin Cancer Treatment Market Insights:
- What was the Nonmelanoma Skin Cancer drugs market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Nonmelanoma Skin Cancer treatment market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
- What are the key findings of the market across 7MM and which country will have the largest Non-melanoma Skin Cancer market size during the study period (2020-2034)?
- At what CAGR, the Non-melanoma Skin Cancer drugs market is expected to grow by 7MM during the study period (2020-2034)?
- What would be the Nonmelanoma Skin Cancer market outlook across the 7MM during the study period (2020-2034)?
- What would be the Non-melanoma Skin Cancer market growth till 2034, and what will be the resultant market Size in the year 2034?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Nonmelanoma Skin Cancer?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan?
- What is the historical Nonmelanoma Skin Cancer patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan?
- What would be the forecasted patient pool of Nonmelanoma Skin Cancer in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Nonmelanoma Skin Cancer?
- Out of all 7MM countries, which country would have the highest prevalent population of Nonmelanoma Skin Cancer during the Study period (2020-2034)?
- At what CAGR the patient population is expected to grow by 7MM during the Study period (2020-2034)?
Current Nonmelanoma Skin Cancer Treatment Market Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Nonmelanoma Skin Cancer treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Nonmelanoma Skin Cancer in the US, Europe, and Japan?
- What are the Nonmelanoma Skin Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Nonmelanoma Skin Cancer?
- How many therapies are in-development by each company for Nonmelanoma Skin Cancer treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Nonmelanoma Skin Cancer treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmelanoma Skin Cancer therapies?
- What are the recent novel therapies, targets, Nonmelanoma Skin Cancer Mechanisms of Action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nonmelanoma Skin Cancer and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the Nonmelanoma Skin Cancer emerging therapies?
- What are the global historical and forecasted of Nonmelanoma Skin Cancer Drugs Market?
Reasons to buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Nonmelanoma Skin Cancer market
- Organize sales and marketing efforts by identifying the best opportunities for Nonmelanoma Skin Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Nonmelanoma Skin Cancer market
- To understand the future market competition in the Nonmelanoma Skin Cancer market
Stay Updated with us for Recent Articles
- Insulet Corporation’s Omnipod® 5 Automated Insulin Delivery System Receives FDA Approval; FDA Gives Green Light to Expand Vericel’s MACI Arthro Label; SkinCure Oncology Announces New Study of Non-melanoma Skin Cancer Through Image-guided Superficial Radiation Therapy; SDC’s BYOD ePRO Solution Clinical Trial; PaceMate® Acquires Paceart Optima™ System; KARL STORZ Acquires a US-headquartered Company
- Latest DelveInsight Blogs